HC Wainwright Reaffirms Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $80.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Celldex Therapeutics’ Q1 2025 earnings at ($0.73) EPS. Other equities […]

Mar 3, 2025 - 09:06

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $80.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Celldex Therapeutics’ Q1 2025 earnings at ($0.73) EPS. Other equities […]